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Abstract
Background This study was to evaluate the efficacy and
safety of triple fixed-dose combination (FDC) therapy with
olmesartan medoxomil (OM) 20 mg, amlodipine (AML)
5 mg, and hydrochlorothiazide (HCTZ) 12.5 mg (OM/
AML/HCTZ 20/5/12.5) in Korean patients with moderate
hypertension not controlled with dual FDC therapy (OM/
HCTZ 20/12.5).
Methods In this multicenter, randomized, double-blind,
parallel-group study, Korean patients aged 20 to 75 years
with stage 2 hypertension who had a mean seated diastolic
blood pressure (msDBP) C100 mmHg were enrolled when
their BP was uncontrolled [mean seated systolic BP
(msSBP)/msDBP [140/90 mmHg or msSBP/msDBP
[130/80 mmHg with diabetes or chronic kidney disease]
with 4-week dual FDC therapy (OM/HCTZ 20/12.5). The
patients were randomized to receive either OM/AML/
HCTZ 20/5/12.5 or OM/HCTZ 20/12.5 once daily for
8 weeks. At the end of 8 weeks, patients with uncontrolled
BP were assigned to receive either OM/AML/HCTZ 40/5/
12.5 or OM/AML/HCTZ 20/5/12.5 in an additional 8-week
open-label extension period.
Results A total of 623 patients received a 4-week run-in
treatment with OM/HCTZ, 341 patients were randomized,
and finally, 167 patients in the OM/AML/HCTZ group and
171 patients in the OM/HCTZ group were analyzed for the
full analysis set. Non-responders after the 8 weeks of
double-blind treatment continued the 8-week open-label
treatment with OM/AML/HCTZ 40/5/12.5 mg (n = 32) or
OM/AML/HCTZ 20/5/12.5 mg (n = 71). After 8 weeks of
double-blind treatment, the changes in msDBP were -9.50
(8.46) mmHg in the OM/AML/HCTZ group and -4.23
(7.41) mmHg in the OM/HCTZ group (both p\ 0.0001 vs.
baseline; p\ 0.0001 between groups). The response rates
for both msSBP and msDBP at week 8 were 65.27 % in the
OM/AML/HCTZ group and 37.43 % in the OM/HCTZ
group (p\ 0.0001 between groups). The response rates for
both msSBP and msDBP at week 16 after open-label
treatment were 18.75 % in the OM/AML/HCTZ 40/5/12.5
group and 46.48 % in the OM/AML/HCTZ 20/5/12.5
group (p = 0.0073 between groups). All medications were
well tolerated.
Conclusion In Korean patients with moderate hyperten-
sion not controlled with dual FDC therapy (OM/HCTZ
20/12.5) as first-line therapy, switching to triple FDC
therapy (OM/AML/HCTZ 20/5/12.5) was associated with
significant BP reductions and greater achievement of BP
goals, and was well tolerated (ClinicalTrials.gov Identifier:
NCT01838850).
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Key Points
In Korean patients with moderate hypertension not
controlled with dual fixed-dose combination (FDC)
as first-line therapy, switching to triple FDC therapy
is safe and effective in reaching target blood
pressure.
Triple FDC therapy can be a safe and effective
alternative for Asian patients with hypertension not
controlled with a dual FDC, including thiazide, in
real-world clinical practice.
1 Introduction
Most patients may need more than one antihypertensive
drug to achieve target blood pressure (BP). Initial treatment
with dual antihypertensive therapy is recommended for
some patients, such as those with a markedly elevated BP
or high/very high cardiovascular risk [1, 2]. In addition,
almost half of patients prescribed an antihypertensive
medication discontinued the treatment by the end of 1 year
[3]. A single-pill combination therapy could simplify the
antihypertensive regimen, particularly in patients with
various comorbidities, which may improve compliance,
persistence, and BP control compared with its corre-
sponding free-drug combinations [2, 4, 5].
Guidelines for the management of hypertension from the
American Society of Hypertension, the International
Society of Hypertension, the Korean Society of Hyper-
tension, the Japanese Society of Hypertension, and other
meta-analysis data favor the use of combinations of two
antihypertensive drugs at fixed doses in a single tablet
[fixed-dose combination (FDC)] because reducing the
number of pills improves adherence and increases the rate
of BP control, minimizing adverse effects [1, 4, 6–9].
Different FDCs of the same two or three drugs are
increasingly becoming available.
Antihypertensive agents with a combination of the
angiotensin receptor blocker (ARB) olmesartan medoxomil
(OM), the calcium antagonist amlodipine (AML), and the
diuretic hydrochlorothiazide (HCTZ) are now available as
an FDC tablet (OM/AML/HCTZ). The triple combination
regimen with OM/AML/HCTZ, including high-dose OM
40 mg, was associated with significant BP reductions
compared with any of the dual combination regimens at
week 12 in the phase III TRINITY (triple therapy with
olmesartan medoxomil, amlodipine besylate, and
hydrochlorothiazide in adult patients with hypertension)
study [10, 11]. According to the subgroup analyses of the
TRINITY trial, OM/AML/HCTZ was more effective for
BP reductions than each of the dual regimens, irrespective
of hypertension severity, age, or sex [10, 12]. Other clinical
studies reported that a triple combination of OM/AML/
HCTZ provides effective BP reduction in patients whose
BP is not controlled with a dual combination of OM/AML
[13, 14]. However, data are limited regarding the efficacy
and safety of dual FDC therapy in comparison with triple
FDC therapy for reducing BP in their standard or low
doses, rather than the higher or maximum doses used in the
clinical trials, as a first-line therapy in actual clinical
practice. The issue that triple FDC therapy can be a safe
alternative for patients with hypertension not controlled
with a dual FDC, including thiazide, is still unresolved.
The purpose of this study was to evaluate the efficacy
and safety of low-dose triple FDC therapy with OM 20 mg,
AML 5 mg, and HCTZ 12.5 mg (OM/AML/HCTZ 20/5/
12.5) in Korean patients with moderate hypertension not
controlled with low-dose dual FDC therapy with OM 20
mg and HCTZ 12.5 mg (OM/HCTZ 20/12.5) (Clini-
calTrials.gov Identifier: NCT01838850).
2 Patients and Methods
2.1 Study Population
Korean men and women aged 20–75 years who had
hypertension were screened for eligibility between April
2013 and January 2014. They were included in the study if
they had newly diagnosed hypertension or had not under-
gone treatment with antihypertensive drugs within 4 weeks
of screening, with a mean seated diastolic BP (msDBP)
C100 mmHg at screening. Patients who had been receiving
a stable dose of antihypertensive drugs for at least 4 weeks
before the run-in period and met the following BP criteria
at screening were also included: monotherapy, msDBP
C95 mmHg; dual combination therapy, msDBP
C90 mmHg; triple combination therapy, 70 mmHg B
msDBP\ 90 mmHg. Patients whose mean seated systolic
BP (msSBP) was C140 mmHg (msSBP C130 mmHg in
subjects with diabetes or chronic kidney disease) and
whose msDBP was C90 mmHg (msDBP C80 mmHg in
subjects with diabetes or chronic kidney disease) were
randomized.
Patients were excluded if they had an msDBP
C115 mmHg or msSBP C200 mmHg measured at
screening and randomization, a minimum–maximum dif-
ference in seated SBP of C20 mmHg or seated DBP of
C10 mmHg in the chosen arm at screening, or a difference
in seated SBP of C20 mmHg and seated DBP of
C10 mmHg in both arms at screening. Patients were also
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excluded if they were hypersensitive to the investigational
product or any of its components; had a medical history of
hypersensitivity to sulfonamide, dihydropyridine, or thi-
azide diuretics; had a history of secondary hypertension or
any of the diseases suspected of secondary hypertension,
symptomatic orthostatic hypotension, uncontrolled dia-
betes mellitus (fasting blood sugar level [200 mg/dl),
severe symptomatic heart failure, ischemic heart disease, or
peripheral vascular disease; had undergone interventions
within 6 months before screening; had clinically significant
arrhythmias (ventricular tachycardia, atrial fibrillation,
atrial flutter, or other arrhythmia considered clinically
significant), hypertrophic obstructive cardiomyopathy,
hemodynamically significant stenosis on the aortic valve or
mitral valve, severe cerebrovascular disorder, known
moderate or malignant retinopathy, any known autoim-
mune disease, or connective tissue disease; required
chronic anti-inflammatory treatment; had anuria or severe
renal failure, severe hepatic failure, biliary obstruction,
biliary cirrhosis, or cholestasis, Addison’s disease, glu-
cose–galactose malabsorption, galactose intolerance, or
Lapp lactase deficiency; had gastrointestinal tract disease
or undergone a surgical operation that may affect absorp-
tion, distribution, metabolism, and excretion of drugs; had
active gastritis or gastrointestinal/rectal bleeding consid-
ered clinically significant by the investigator; had active
inflammatory bowel syndrome within the last 12 months;
had a history of or were suspected of drug or alcohol abuse;
were pregnant or lactating; or were women of childbearing
potential who did not agree to use appropriate contracep-
tive methods such as progestin hormone therapy (oral,
implant), intrauterine device, barrier methods of contra-
ception [condom or occlusive cap (diaphragm or cervi-
cal/vault caps) with spermicide], male sterilization, or true
abstinence.
2.2 Study Design and Procedures
This 16-week, multicenter, randomized, double-blind,
parallel-group study was conducted at 39 locations in the
Republic of Korea. Participants who received OM/HCTZ
20/12.5 mg for the 4-week run-in period but who did not
meet their BP goals (msSBP/msDBP\140/90 mmHg or
msSBP/msDBP\130/80 mmHg in subjects with diabetes
or chronic kidney disease; non-responders) could start
receiving either the triple FDC therapy with OM/AML/
HCTZ 20/5/12.5 mg or the dual FDC with OM/HCTZ
20/12.5 mg and a matched placebo during a randomized,
8-week, double-blind period. The non-responders after the
8 weeks of treatment could continue the 8-week open-label
period with switching to OM/AML/HCTZ 40/5/12.5 mg
from OM/AML/HCTZ 20/5/12.5 mg or OM/AML/HCTZ
20/5/12.5 mg from OM/HCTZ 20/12.5 mg (Fig. 1).
BP was measured at all study visits with a cuff of an
appropriate size by using standard mercury sphygmo-
manometer calibrated on a regular basis at each study sites.
Measurements were taken with the patient in a seated
position after a 5-min rest. BP measurements were obtained
three times at 2-min intervals in both arms. The arm was
chosen if the BP was higher than the other arm. The mean
of the last two measurements was recorded as the BP value
for that visit. Patients were excluded from the study if
msDBP was C115 mmHg or msSBP was C200 mmHg at
screening and randomization. All of the patients provided
informed consent, and the study protocol was approved by
the institutional review board at each location. This study
was prospectively registered at ClinicalTrials.gov: Identi-
fier NCT01838850.
2.3 Efficacy Assessment
The primary endpoint was the change in msDBP from
randomization to the end of the 8-week double-blind
treatment period for triple FDC therapy compared with
dual FDC therapy. The secondary endpoints included the
change in the msSBP from baseline to the end of the
8-week treatment; changes in the msDBP and msSBP
from randomization to 4 weeks of treatment; the per-
centage of patients who achieved their BP goal (msSBP/
msDBP \140/90 mmHg or msSBP/msDBP \130/
80 mmHg with diabetes or chronic kidney disease) at
weeks 4, 8, and 16; and the change in msDBP and msSBP
from week 8 to week 16 during the open-label treatment
period. Responders were defined as patients who reached
the BP goal at week 8, and non-responders were those
who did not.
2.4 Safety Assessment
Safety assessments included adverse events (AEs), clinical
laboratory examinations (chemistry, hematology, and uri-
nalysis), vital signs (seated BP and seated heart rate),
physical examinations, and 12-lead electrocardiographs.
Laboratory tests were performed at each study site and
were assessed before screening, at day 0, and at weeks 4, 8,
and 16. Seated BP and heart rate were measured, and
physical examinations were performed at all study visits.
Twelve-lead electrocardiographs were obtained at the
screening visit and at weeks 8 and 16. Patient adherence
was monitored by assessing the tablet count from drug
packages returned at each visit. The severity of AEs (mild,
moderate, or severe) and their relationship to treatment
(certainly related, probably related, possibly related, unli-
kely to be related, or not related to the study drug) were
assessed and reported based on the judgment of the
investigators.
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2.5 Statistical Analysis
The hypothesis in this study was that triple FDC therapy
with OM/AML/HCTZ is superior to dual FDC with OM/
HCTZ in reducing msDBP. The mean change in DBP in
the TRINITY study was -16.5 ± 10.8 mmHg with dual
FDC therapy (OM/HCTZ) and -21.5 ± 10.3 mmHg with
triple FDC therapy (OM/AML/HCTZ), resulting in an
effect size of -5 mmHg for superiority margin [10]. In
general, the smallest effect size was -2 mmHg between
the treatment groups in most clinical trials regarding FDC
therapy [15]. We selected -3.5 mmHg as the median value
between -5 and -2 mmHg and as the superiority margin
for the difference in the msDBP between treatments. The
pooled standard deviation (SD) from the TRINITY study
was considered to be 10.55 mmHg. All parameters were
assumed as follows: the superiority margin for the differ-
ence in the msDBP between treatments (e) = -3.5 mmHg;
significance level (a) = 0.05; power of 0.80 (b = 0.2); and
standard deviation (r) = 10.55 mmHg. An estimated
sample size of 143 patients per treatment group would be
required, and 338 patients (169 per treatment group) were
needed, considering a dropout rate of 15 %.
For continuous variables, the mean (SD), median, and
minimum and maximum values were determined and
compared using the independent t test or Wilcoxon rank-
sum test between groups and the paired t test or Wilcoxon
signed-rank test within a group. For categorical demo-
graphic variables, absolute and relative frequencies were
determined and compared using the v2 test or Fisher’s
exact test. The absolute and relative frequencies of msSBP
\140 mmHg, msDBP \90 mmHg, or both, and the
response rates at weeks 4, 8, and 16 of treatment were
determined and compared using the v2 test or Fisher’s
exact test. The least-squares mean changes in the msDBP
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Fig. 1 Study flow and patient disposition. AML amlodipine, BP
blood pressure, HCTZ hydrochlorothiazide, OM olmesartan medox-
omil. Non-responders were defined as patients who did not meet BP
goals [msSBP/msDBP \140/90 mmHg (msSBP/msDBP \130/
80 mmHg in patients with diabetes or chronic kidney disease)]
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significance was defined as a p\ 0.05. No adjustments
were made for multiplicity. Statistical analyses were per-




A total of 662 patients were screened; 623 patients
underwent a 4-week run-in treatment with OM/HCTZ, 209
patients achieved their BP goals (209/623, 33.6 %), 341
patients were randomized to either the OM/AML/HCTZ
group (n = 169) or the OM/HCTZ group (n = 172), and
316 patients completed the double-blind treatment. Two
patients in the OM/AML/HCTZ group and one patient in
the OM/HCTZ group were not assessed at the primary
endpoint. Therefore, 167 patients in the OM/AML/HCTZ
group and 171 patients in the OM/HCTZ group were
analyzed for the full analysis set. The non-responders after
the 8 weeks of treatment (32 patients in the OM/AML/
HCTZ group and 73 patients in the OM/HCTZ group)
continued the 8-week open-label treatment with OM/AML/
HCTZ 40/5/12.5 mg or OM/AML/HCTZ 20/5/12.5 mg,
respectively (Fig. 1). The baseline demographic and clini-
cal characteristics, including age, sex, weight, height, body
mass index, smoking status, alcohol intake, duration of
hypertension, presence of family history of hypertension,
prevalence of diabetes and chronic kidney disease, and
antihypertensive drug history did not differ significantly
between the two groups (Table 1). Medication adherence
appeared to be similar across treatment groups, ranging
from 96.3 to 98.5 %.
3.2 Efficacy
After 8 weeks of double-blind treatment, the changes in
msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ
group and -4.23 (7.41) mmHg in the OM/HCTZ group
(both p\ 0.0001 vs. baseline; p\ 0.0001 between groups;
Fig. 2a). The changes in msSBP from baseline to the end of
Table 1 Baseline demographic and clinical characteristics of the subjects
Characteristics OM/AML/HCTZ 20/5/12.5 (n = 167) OM/HCTZ 20/12.5 (n = 171) All patients (n = 338)
Age, years 56.1 ± 10.1 56.4 ± 10.7 56.3 ± 10.4
Female 52 (31.1) 51 (29.8) 103 (30.5)
Weight, kg 73.6 ± 12.3 73.8 ± 11.4 73.7 ± 11.8
Height, cm 166.3 ± 8.3 165.6 ± 8.1 165.9 ± 8.2
BMI, kg/m2 26.5 ± 3.3 26.8 ± 3.3 26.7 ± 3.3
msDBP, mmHg 94.4 ± 6.2 94.5 ± 6.1 94.4 ± 6.1
msSBP, mmHg 145.3 ± 8.7 147.7 ± 11.0 146.5 ± 10.0
Heart rate, rate/minute 73.8 ± 9.6 74.0 ± 9.5 73.2 ± 9.5
Smoking history
Current 35 (21.0) 32 (18.7) 67 (19.8)
Past 36 (21.6) 42 (24.6) 78 (23.1)
Never 96 (57.5) 97 (56.7) 193 (57.1)
Alcohol intake
Current 97 (58.1) 87 (50.9) 184 (54.4)
Past 10 (6.0) 10 (5.8) 20 (5.9)
None 60 (35.9) 74 (43.3) 134 (39.6)
Duration of hypertension, years 8.2 ± 7.2 9.4 ± 8.6 8.8 ± 8.0
Family history of hypertension 81 (48.5) 80 (46.8) 161 (47.6)
History of antihypertensive drugs 128 (76.6) 125 (73.1) 253 (74.9)
Monotherapy 25 (19.5) 23 (18.4) 48 (19.0)
Double combination 57 (44.5) 65 (52.0) 122 (48.2)
Triple combination 46 (35.9) 37 (29.6) 83 (32.8)
Diabetes mellitus 33 (19.8) 33 (19.3) 66 (19.5)
Chronic kidney disease 3 (1.8) 8 (4.7) 11 (3.3)
Data are presented as mean ± SD or n (%)
AML amlodipine, BMI body mass index, FDC fixed-dose combination, HCTZ hydrochlorothiazide, msDBP mean seated diastolic blood pressure,
msSBP mean seated systolic blood pressure, OM olmesartan medoxomil, SD standard deviation
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the 8-week treatment were -16.30 (12.37) mmHg in the
OM/AML/HCTZ group and -9.01 (12.90) mmHg in the
OM/HCTZ group (both p\ 0.0001 vs. baseline;
p\ 0.0001 between groups; Fig. 2b).
The changes in msDBP and msSBP from randomization
to after 4 weeks of treatment were -11.39 (8.34) mmHg
and -14.75 (12.50) mmHg, respectively, in the OM/AML/
HCTZ group (both p\ 0.0001 vs. baseline) and -5.74
(9.22) mmHg and -7.93 (11.99) mmHg, respectively, in
the OM/HCTZ group (both p\ 0.0001 vs. baseline; both
p\ 0.0001 between groups; Fig. 2).
The percentages of the patients who achieved their BP
goal for both msSBP and msDBP at week 4 were 53.89 %
in the OM/AML/HCTZ group and 28.65 % in the OM/
HCTZ group (p\ 0.0001 between groups). The response
rates for both msSBP and msDBP at week 8 were 65.27 %
in the OM/AML/HCTZ group and 37.43 % in the OM/
HCTZ group (p\ 0.0001 between groups; Table 2).
The changes in msDBP from week 8 to week 16 during
the open-label treatment period were -5.38 (8.86) mmHg
in the OM/AML/HCTZ 40/5/12/5 group (p\ 0.0017 vs.
baseline) and -11.07 (8.22) mmHg in the OM/AML/
HCTZ 20/5/12.5 group (p\ 0.0001 vs. baseline;
p\ 0.0020 between groups). The changes in msSBP after
8 weeks of open-label treatment were -9.22 (10.33)
mmHg in the OM/AML/HCTZ 40/5/12/5 group
(p\ 0.0001 vs. baseline) and -16.58 (13.66) mmHg in the
OM/AML/HCTZ 20/5/12.5 group (p\ 0.0001 vs. base-
line; p\ 0.0078 between groups; Fig. 3). The response
rates for both msSBP and msDBP at week 16 were
18.75 % in the OM/AML/HCTZ 40/5/12.5 group and
46.48 % in the OM/AML/HCTZ 20/5/12.5 group
(p = 0.0073 between groups; Table 2).
The least-squares mean changes in msDBP from ran-
domization to after 8 weeks of double-blind treatment were
not significantly different according to sex, age, smoking
status, and body mass index (Fig. 4).
3.3 Safety
Excluding one patient in the OM/AML/HCTZ group (due
to the lack of detailed safety information), we assessed the
safety profile in 340 patients (168 in the OM/AML/HCTZ
group and 172 in the OM/HCTZ group). The overall
incidence of AEs was relatively low and not significantly
different in both treatment groups, and most AEs were mild
(81 of 340 patients, 23.82 %) and not considered to be drug
related (83 of 340 patients, 24.41 %; Table 3). A total of 46
AEs in the OM/AML/HCTZ group and 51 in the OM/
HCTZ group were recorded. Five patients in the OM/AML/
HCTZ group (2.98 %) and six patients in the OM/HCTZ
group (3.49 %) experienced six and eight adverse drug
reactions, respectively. Three patients experienced serious
AEs. In the OM/AML/HCTZ group, one patient had acute
tonsillitis and another underwent minor surgery for a cer-
vical polyp. A patient in the OM/HCTZ group died after
sudden cardiac arrest with hyperkalemia and with the
probable diagnosis of acute myocardial infarction (de-
scribed and reported as not related to the study drug by the
investigator).
Discontinuations due to AEs occurred in four (2.38 %)
of 168 patients in the OM/AML/HCTZ group. The reasons
for discontinuation, each of which occurred in one patient
(0.6 %), were dizziness, fatigue, and palpitation. Three
other patients reported hypotension, pre-syncope, or cough,
respectively, as a cause of discontinuation. Four (2.33 %)
of 172 patients in the OM/HCTZ group discontinued their
medications because of constipation, dizziness, or head-
ache for (n = 3 patients each), and one patient died, as
described previously.
4 Discussion
In the present study, we found that Korean patients with
moderate hypertension who did not achieve their BP goals
after the 4-week treatment with initial low-dose dual FDC
























































Fig. 2 Changes in mean seated diastolic blood pressure (msDBP)
(a) and mean seated systolic blood pressure (msSBP) (b) from
randomization to weeks 4 and 8 of the double-blind treatment. AML
amlodipine, HCTZ hydrochlorothiazide, OM olmesartan medoxomil.
*p\ 0.0001 vs. OM/HCTZ
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improvement in BP control after switching to low-dose
triple FDC therapy (OM/AML/HCTZ 20/5/12.5 mg),
which was well tolerated. Among the non-responders of the
4-week run-in treatment who were randomized and swit-
ched to triple FDC therapy during the 8-week double-blind
treatment, the percentage of patients who achieved their BP
goal at week 8 was about two-thirds (65.27 %), but only
about one-third (37.43 %) of the patients who continued
dual FDC therapy achieved their target BP. For tolerability,
only 8 of 340 patients (2.35 %) discontinued their
medications.
Initiating antihypertensive therapy with a combination
of two drugs is associated with a reduced risk of
Table 2 The percentage of patients (response rate) achieving blood pressure goala at weeks 4, 8, and 16
BP goal Time OM/AML/HCTZ (n = 167) OM/HCTZ (n = 171) p valueb
msSBP\140 mmHg Week 4 70.66 43.86 \0.0001
Week 8 74.85 47.95 \0.0001
msDBP\90 mmHg Week 4 58.68 35.09 \0.0001
Week 8 70.66 42.69 \0.0001
Both Week 4 53.89 28.65 \0.0001
Week 8 65.27 37.43 \0.0001
BP goal Time OM/AML/HCTZ 40/5/12.5
(n = 32)
OM/AML/HCTZ 20/5/
12.5 (n = 71)
p valueb
SBP\140 mmHg Week 16 37.50 60.56 0.0299
DBP\90 mmHg Week 16 31.25 59.15 0.0088
Both Week 16 18.75 46.48 0.0073
Values are presented as %
AML amlodipine, HCTZ hydrochlorothiazide, msDBP mean seated diastolic blood pressure, msSBP mean seated systolic blood pressure, OM olmesartan
medoxomil
a msSBP\140 mmHg, msDBP\90 mmHg, or both; msSBP\130 mmHg, msDBP\80 mmHg, or both in patients with diabetes or chronic kidney
disease


















































Fig. 3 Changes in mean seated diastolic blood pressure (msDBP)
(a) and mean seated systolic blood pressure (msSBP) (b) from week 8
to week 16 during the open-label period. AML amlodipine, HCTZ
hydrochlorothiazide, OM olmesartan medoxomil. *p = 0.0434,







































Fig. 4 Least-squares (LS) mean change in the mean seated diastolic
blood pressure (msDBP) from randomization to 8 weeks of double-
blind treatment according to sex, age, smoking status, and body mass
index. *Adjusted for age, smoking, alcohol, and body mass index
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medication discontinuation [16]. The other advantages of
this approach are the maximized BP reduction in the
patients with markedly elevated BP, rapid BP control
(especially in patients at high cardiovascular risk), and
minimized adverse effects [2, 4]. Most guidelines favor the
combination of an angiotensin-converting enzyme inhibitor
or ARB, and thiazide diuretic or calcium antagonist [2, 4,
9]. They also recommend the use of FDCs because
reducing the pill burden improves adherence and increases
the BP control rate. In addition, to overcome the incon-
venience and difficulty in increasing the dose of one drug
in FDC therapy, different FDCs with different doses of
each component are available.
When initiating a combination of two drugs, doses can
be increased to achieve the BP target, or adding a third
drug from different classes can be considered. A meta-
analysis showed that combining two agents from any
classes of antihypertensive drugs increases the BP reduc-
tion much more than increasing the dose of one drug, and
the reduction in BP may be approximately fivefold greater
with two agents than with doubling the dose of one agent
[6]. In this study, we tried to test the efficacy and safety of
‘standard or low-dose’ triple FDC (OM/AML/HCTZ 20/5/
12.5) in patients with moderate hypertension not controlled
with ‘initial low-dose’ dual FDC therapy (OM/HCTZ
20/12.5), not with ‘maximum or high doses’ as done in the
TRINITY trial [10]. In addition, the entire TRINITY trial
population only included about 2 % Asians, and their mean
body mass index was 33 kg/m2 [10]. In contrast, our study
enrolled only Koreans (all Asians) who were much smaller
(mean body mass index, 26.7 kg/m2) than the westerners,
which means that in real practice Asians may need lower
doses of anti-hypertensive drugs than larger-sized west-
erners. Because FDC therapy is less expensive than the
total price of each single drug and because FDC therapy as
a first-line therapy is covered by health insurance, FDC
therapy has a combined medical and economic advantage
for patients with hypertension in South Korea.
We chose OM with HCTZ as first-line FDC therapy
because FDC therapy including an angiotensin-converting
enzyme inhibitor is not available in South Korea. Second,
an ARB combined with a diuretic rather than a calcium
Table 3 Adverse events during double-blind treatment
Adverse events OM/AML/HCTZ 20/5/12.5 (n = 168) OM/HCTZ 20/12.5 (n = 172)
Any adverse events 33 (19.64)a, 46 events 34 (19.77)a, 51 events
Severity
Mild 41 (24.40) 40 (23.26)
Moderate 5 (2.98) 10 (5.81)
Severe 0 1 (0.58)
Causality
Related 6 (3.57) 8 (4.65)
Certainly/probably/possibly/unassessable 2/1/2/1 0/1/5/2
Not related 40 (23.81) 43 (25.00)
Unlikely/not related 14/26 11/32
Adverse drug reactions 5 (2.98)a, 6 events 6 (3.49)a, 8 events
Dizziness 2 (1.19) 2 (1.16)
Pre-syncope 1 (0.60) 0
Syncope 0 1 (0.58)
Peripheral edema 0 2 (1.16)
Generalized edema 0 1 (0.58)
Fatigue 1 (0.60) 0
Constipation 0 1 (0.58)
Cough 1 (0.60) 0
Pruritus 0 1 (0.58)
Hypotension 1 (0.60) 0
Serious adverse events 2 (1.19)b, 2 events 1 (0.58)c, 3 events
Data are presented as n (%) patients
AML amlodipine, HCTZ hydrochlorothiazide, OM olmesartan medoxomil
a Some patients had more than one event
b One had acute tonsillitis and one underwent minor surgery for cervical polyp
c The patient died after sudden cardiac arrest with hyperkalemia and the diagnosis of probable acute myocardial infarction
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antagonist showed more clinical benefits than combined
placebo or beta-blocker and diuretic in randomized con-
trolled trials [17–19]. In addition, the combination of an
ARB with a diuretic has advantages because of the syn-
ergistic BP-lowering effects and because an ARB offsets
the adverse effects of a diuretic on electrolyte and glucose
metabolism. In this study, among 623 patients who
underwent the 4-week run-in treatment with dual FDC
therapy (OM/HCTZ 20/12.5), 209 achieved their BP goals
(209/623, 33.6 %). Compared with dual FDC therapy, tri-
ple FDC therapy was associated with a significantly higher
percentage of patients who achieved their BP goal when
the BP was not controlled with dual FDC therapy as first-
line therapy. Interestingly, among the non-responders after
the 8-week double-blind treatment who were allocated to
triple FDC therapy (OM/AML/HCTZ) with a double dose
of ARB OM, the response rate was less than one-fifth
(18.75 %). In contrast, among the patients who received
triple FDC therapy, including the calcium antagonist
(AML) switched from double FDC therapy (OM/HCTZ),
about one-half (46.48 %) achieved their target BP. This
may suggest that patients who are not responsive to dual
FDC therapy, including an ARB and a thiazide, could be
switched to triple FDC therapy by adding a different class
of drug (a calcium antagonist) for a safe and more effective
BP reduction than doubling the dose of an agent.
4.1 Study Limitations
Our study was limited by its short treatment period and
relatively small cohort size. Therefore, the safety results
should be interpreted with caution, and a large-scale study
may be needed to determine the long-term safety and
clinical outcomes of triple FDC therapy.
5 Conclusions
In Korean patients with moderate hypertension not con-
trolled with dual FDC therapy with OM/HCTZ 20/12.5 as a
first-line therapy, switching to triple FDC therapy with
OM/AML/HCTZ 20/5/12.5 was associated with significant
BP reductions and greater achievement of BP goals, and
was well tolerated. These findings may provide useful
information to clinicians in choosing triple FDC therapy in
Asian patients with moderate hypertension not controlled
with dual FDC therapy for safe and effective BP reduction
in actual clinical practice.
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